The Overlap of Henoch-Schönlein Purpura Nephritis and IgA Nephropathy

Henoch-Schönlein purpura (HSP) and IgA nephropathy both involve kidney inflammation driven by IgA-mediated immunologic damage. This article examines their intertwined relationship and ongoing debate whether HSP nephritis represents a manifestation of broader HSP disease versus a continuum with isolated IgA nephropathy restricted to the kidneys.

Introduction to Henoch-Schönlein Purpura and IgA Nephropathy

Henoch-Schönlein purpura (HSP) is an IgA-mediated small vessel vasculitis distinguished by the clinical tetrad of palpable purpura rash, abdominal pain, arthritis and kidney involvement termed HSP nephritis. First described in 1837, it predominantly affects children aged 4-7 years old.

IgA nephropathy is characterized by IgA immune complex deposition in the kidney glomeruli causing inflammation termed IgA nephritis. First recognized by Berger in 1968 as “Berger’s disease”, it typically presents in the late teens to early 30s without systemic signs like rash or joint pains.

Both HSP nephritis and IgA nephropathy feature mesangial IgA deposits leading to hematuria and variable proteinuria on urinalysis. A subset in both groups slowly progresses to chronic kidney dysfunction and end stage renal disease (ESRD).

The Pathophysiology of HSP and IgA Nephropathy

In HSP, various external triggers like viruses or medications are postulated to initiate abnormal glycosylation of IgA1 antibodies. These poorly galactosylated IgA complexes likely resist normal removal, so deposit along vascular bases provoking systemic and organ inflammation. Exactly how and why the kidneys are ultimately targeted remains unclear.

By contrast, primary IgA nephropathy lacks preceding triggers or extra-renal disease. Inherited defects in IgA1 production allow poorly glycosylated IgA to accumulate solely in the kidney glomeruli through unknown steps, activating downstream inflammatory and fibrotic pathways. 32-47% of variability implicates genetic factors by family clustering patterns.

Clinicopathologic Similarities Between HSP Nephritis and IgA Nephropathy

Light Microscopy Appearance

Renal biopsy in both diseases reveals similar patterns of mesangial hypercellularity and matrix expansion under light microscopy initially, with superimposed inflammatory cell infiltration. Later glomerulosclerosis and tubulointerstitial scarring patterns resemble each other as well.

Immunofluorescence Staining

The pathognomonic finding in both is granular glomerular IgA antibody deposition, typically accompanied by C3 complement component staining as well on immunofluorescence. The density and distribution of IgA staining closely overlaps between HSP nephritis and IgA nephropathy specimens.

Electron Microscopy

Ultrastructural enlargement of mesangial areas shows electron-dense immune complex deposition in similar areas for both conditions. Foot process effacement denotes early podocyte injury.

Overall, the kidney histopathology cannot reliably distinguish primary IgA nephropathy from HSP nephritis, supporting potential shared immunopathogenesis.

Clinical Differences Between HSP Nephritis and IgA Nephropathy

However, some key clinical differences argue for separate disease entities:

Age Incidence

HSP typically begins early, peaking at ages 4 to 6 years. Meanwhile, Primary IgA nephropathy very rarely affects children under age 10, instead presenting in the late teens to 30s.

Systemic Symptoms

By definition, HSP causes the multi-organ syndrome of rash, abdominal pain, joint swelling and nephritis. IgA nephropathy is confined to the kidneys without extra-renal features in most cases.

Renal Presentation

HSP nephritis arises more acutely alongside other flares, often with dramatic visible hematuria. IgA nephropathy follows a more indolent course diagnosed incidentally on routine screens for microscopic hematuria noticed over time.

Outcomes

HSP overall carries a favorable prognosis in children, with nephritis resolving fully about 90% of the time after the acute episode. IgA nephropathy is characterized by slowly progressive chronic dysfunction over years regardless of supportive care.

These contrasts argue for distinct processes driving the respective diseases.

Theories Explaining the HSP-IgA Nephropathy Relationship

Various conceptual models attempt to integrate these clinicopathologic correlations and inconsistencies:

Part of an HSP Disease Spectrum

Some postulate HSP represents a systemic immune disorder where the kidney manifestation of HSP nephritis simply mirrors changes seen in primary IgA nephropathy incidentally. The extra-renal symptoms reflect associated inflammatory foci rather than separate disease processes.

Site Specific Manifestations of Common Susceptibility

Conversely, the same inherited risks yielding the glycan-deficient IgA antibodies in IgA nephropathy may produce subtle systemic symptoms in a subset upon encountering environmental triggers. The determining local factors explaining organ tropism remain elusive.

Truly Distinct But Overlapping Entities

Finally, HSP and IgA nephropathy may constitute related but distinct syndromes linked via similar immunoglobulin deposition mechanisms but with differing tempo and triggers. Their co-occurrence within individuals and families better defines common pathways.

In all probability, the pathogenesis likely involves interconnected pathways more complex than any singular unifying theory accommodates fully.

Documented Disease Transformation Between HSP and IgA Nephropathy

Further evidencing their potential interrelatedness, several reports confirm patients with known IgA nephropathy later developing systemic HSP years after their initial diagnosis. The opposite transition from overt HSP to apparent IgA nephropathy has also occurred.

In the largest pediatric series spanning 35 years at a single Swiss center, 3.6% of HSP patients subsequently developed biopsy-confirmed IgA nephropathy. The latency from initial HSP presentation to later kidney-limited disease averaged 7 years. Conversely, a smaller subset of children originally diagnosed with primary IgA nephropathy developed extra-renal HSP years later.

Such crossover between the conditions argues for at least partially shared susceptibility and mechanisms in a portion of patients.

HSP and IgA Nephropathy: Contrasting Treatment and Prognosis

Despite their overlaps, approaches and anticipated outcomes differ:

HSP Treatment Priorities

With HSP, the benign self-limited course warrants conservative monitoring for most children initially. Corticosteroids are reserved for refractory abdominal or joint pain. Monitoring kidney function helps detect nephritis needing immunosuppression to prevent ascending chronic damage.

IgA Nephropathy Treatment Goals

In IgA nephropathy, supporting kidney health is paramount throughout given its consistent progression. Blocking the renin-angiotensin axis and optimized blood pressure control protect glomeruli regardless of symptoms. Steroids may benefit those with proteinuria over 1 gram per day.

Prognosis Differences

Most pediatric HSP resolves fully by 6-8 weeks with no permanent sequelae. Yet despite multi-drug regimens, 30-50% of IgA nephropathy patients reach end stage kidney disease by 20 years out from diagnosis given relentless scarring disease course.

Remaining Unanswered Questions in HSP Nephritis

While connections exist between HSP and IgA nephropathy, ongoing inquiries seek clarity on remaining issues like:

Why Does HSP Largely Spare Adults?

The peak age of 4-6 years in HSP remains unexplained. If due solely to an exaggerated immune response, older individuals should also demonstrate some susceptibility. Yet unlike IgA nephropathy, HSP rarely begins after middle age.

How Does Primary IgA Nephropathy Propagate Without Systemic Triggers?

The initial steps selectively targeting the kidney without inciting systemic findings imply distinct intrinsic glomerular vulnerabilities. Defining the genes and proteins specifically enabling isolated renal IgA deposition despite abundant circulating levels could unlock HSP origins as well.

When Does Atypical HSP Overlap with IgA Nephropathy?

Rare instances of apparent HSP lacking the classic skin rash, or adults presenting with purpura and kidney disease blur diagnostic boundaries. Identifying additional biomarkers confirming a systemic disorder despite absence of pathognomonic signs would improve classification accuracy.

Why Do Some Patients Transition Between the Two?

The drivers causing sequential HSP and IgA nephropathy years apart in the minority of crossover cases remain speculative. Mapping more converted patients promises to reveal additional environmental exposures or biomarkers that temporarily shift manifestations.

How Does Management and Prognosis Compare in Suspected Overlap Cases?

Whether patients with atypical HSP and IgA-type kidney pathology should be managed as per classic HSP guidelines versus regimens for primary IgA nephritis remains debated. Clinical outcomes data would better direct practice but requires unambiguous categorization.

Further scrutinizing patients on both extremes of the HSP-IgA nephropathy spectrum will provide perspicacity on disease origin, relationships and targeted management for these forms of damaging glomerulonephritis sharing common immunologic underpinnings.

Conclusion and Takeaway Points

In summary regarding HSP nephritis and IgA nephropathy:

• Kidney histopathology in both conditions is remarkably similar and indistinguishable.
• Some clinical characteristics and demographics contrast between the two entities.
• A proportion of patients convert from HSP to IgA nephropathy years later, confirming a relationship.
• Clear triggers provoking systemic HSP likely involve additional steps selectively attacking the kidneys to yield isolated IgA glomerular damage.
• Further study on pathology and mutated genes in crossover patients promises to unravel mysteries still surrounding the nature and origin of these forms of immune complex-mediated kidney injury.

While more a disease spectrum than binary classification, understanding nuances that tilt patients along the HSP-IgA nephropathy continuum guides management.

Rate this post

The post The Overlap of Henoch-Schönlein Purpura Nephritis and IgA Nephropathy appeared first on Mirari Doctor.

source https://miraridoctor.com/blog/henoch-schonlein-purpura-iga-nephropathy